Show
Sort by
-
Dupilumab improves objective, subjective, and health-related quality of life outcomes in chronic rhinosinusitis with nasal polyps (CRSwNP), regardless of BMI≥ 30 kg/m2 or weight≥ 90 kg : post-hoc analysis of the SINUS-24 and SINUS-52 studies
(2022) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. In Journal of Allergy and Clinical Immunology 149(2). p.AB143-AB143 -
International consensus statement on allergy and rhinology : rhinosinusitis 2021
-
EPOS2020 : development strategy and goals for the latest European Position Paper on Rhinosinusitis
-
EPOS 2012 : European position paper on rhinosinusitis and nasal polyps 2012 : a summary for otorhinolaryngologists
-
European position paper on rhinosinusitis and nasal polyps 2012